Continued good progress for VRUS in the clinic to be sure. But, how much more upside do we see for the stock at its ~$1.2B market cap, short of a buyout offer? I.e., would a partnership for any of its HCV nukes propel the stock materially higher from the current market cap?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.